Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
NCT04294498Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2020
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Started Nov 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04294498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294498.